Clinical trial · Observational
LINC00511/miR-185-3p Axis and miR-301a-3p Markers for Breast Cancer Diagnosis
Competitive Endogenous Role of the LINC00511/miR-185-3p Axis and miR-301a-3p From Liquid Biopsy as Molecular Markers for Breast Cancer Diagnosis
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Breast cancer is a leading cause of death among women globally, with significant incidence in Egypt. It is characterized by aggressive behavior and resistance to treatment, necessitating early detection methods. Research has revealed that many cancer-related mutations are in non-coding DNA, including microRNAs (miRNAs) and long non-coding RNAs (LncRNAs). miRNAs like miR-185-3p and miR-301a, and LncRNAs such as LINC00511, are potential biomarkers for cancer diagnosis due to their roles in gene regulation and stability in circulation. This study aims to explore the diagnostic utility of these biomarkers in breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Early Diagnosed Breast Cancer | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Control
- description
- free from any medical, psychosocial, emotional conditions, or cancer (age interval was 28-82) were included in the study as well, matched with BC patients' group in sex and race, menopausal status, and randomly chosen from the female Egyptian population.
- label
- BC patients
- description
- full family disease/cancer history was recorded, as well as patients' previous surgical procedures, other than breast surgery, that do not affect the tumor burden, such as splenectomy, tonsillectomy, cesarean birth, and plastic surgery, offspring numbers, menopausal or not, and taking hormonal contraceptives or not. Patients' individual current cancer status and the tumor clinical assessment, done at the NCI, using the tumor-node-metastasis (TNM) categorization (43) and the Bloom-Richardson Scale for histological grading (44), were collected from patients' data files, after a biopsy was taken at the time of BC examination
Primary outcomes (3)
- measure
- 1. Analyze the expression level of two miRNA (miR-185-3p, miR-301a) and their predicted interacted lncRNA (LINC00511)
- timeFrame
- 12 Month
- description
- as minimal noninvasive molecular markers for diagnosing the primary breast cancer.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 28 Years
- Maximum age
- 82 Years
Show eligibility criteria text
Inclusion Criteria: * were being an adult female, with breast invasive carcinoma of no specific type, confirmed pathologically Exclusion Criteria: * Patients with: * were blood disease, any cancer other than BC, liver cirrhosis, and uterine and urinary bladder diseases, or metastatic BC patients who received chemo/radiotherapy, or had previous mastectomy.
References
Publications (0)
Data not yet available